Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression

International Journal of Cancer

Volumn 137, Issue 7, 2015, Pages 1574-1586

  Barboro, Paola ^a   Ferrari, Nicoletta ^a   Capaia, Matteo ^a   Petretto, Andrea ^b   Salvi, Sandra ^a   Boccardo, Simona ^a   Balbi, Cecilia ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

loop; matrix attachment regions (MARs); nuclear matrix; PARP inhibitors; PARP 1; prostate cancer

Indexed keywords

HISTONE H3; LAMIN A; LAMIN B; MATRIX ATTACHMENT REGION BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NUCLEAR MATRIX PROTEIN; VELIPARIB; BENZIMIDAZOLE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN; PARP2 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; CELL COMPARTMENTALIZATION; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; GLEASON SCORE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RADICAL RETROPUBIC PROSTATECTOMY; SOUTHERN BLOTTING; TUMOR GROWTH; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL GROWTH; DISEASE COURSE; DRUG EFFECTS; MATRIX ATTACHMENT REGION; METABOLISM; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

BENZIMIDAZOLES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; MALE; MATRIX ATTACHMENT REGION BINDING PROTEINS; MATRIX ATTACHMENT REGIONS; NEOPLASMS, HORMONE-DEPENDENT; NUCLEAR MATRIX-ASSOCIATED PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS;

EID: 84926443440     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29531     Document Type: Article

References (52)

1. Siegel R, Ma J, Zou Z, et al,. Cancer statistics. CA Cancer J Clin 2014; 64: 9-29.
2. Mackinnon AC, Yan BC, Joseph LJ, et al,. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med 2009; 133: 1033-40.
3. Wyatt AW, Mo F, Wang Y, et al,. The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian J Androl 2013; 15: 301-8.
4. Baca SC, Prandi D, Lawrence MS, et al,. Punctuated evolution of prostate cancer genomes. Cell 2013; 153: 666-77.
5. Mirkovitch J, Mirault ME, Laemmli UK,. Organization of the higher-order chromatin loop: specific DNA attachment sites on nuclear scaffold. Cell 1984; 39: 223-32.
6. Jackson DA, Cook PR,. The structural basis of nuclear function. Int Rev Cytol 1995; 162a: 125-49.
7. Boulikas T,. Chromatin domains and prediction of MAR sequences. Int Rev Cytol 1995; 162a: 279-388.
8. Chattopadhyay S, Pavithra L., MARs and MARPs: key modulators of gene regulation and disease manifestation. In:, Kundu TK, Dasgupta D,. Chromatin and Disease. New York: Springer, 2007; 641: 213-30.
9. Razin SV,. Chromosomal DNA loops may constitute basic units of the eukaryotic genome organization and evolution. Crit Rev Eukaryot Gene Expr 1999; 9: 279-83.
10. Kantidze OL, Razin SV,. Chromatin loops, illegitimate recombination, and genome evolution. Bioessays 2009; 31: 278-86.
11. Galande S,. Chromatin (dis)organization and cancer: BUR-binding proteins as biomarkers for cancer. Curr Cancer Drug Targets 2002; 2: 157-90.
12. Gluch A, Vidakovic M, Bode J,. Scaffold/matrix attachment regions (S/MARs): relevance for disease and therapy. Handb Exp Pharmacol 2008; 186: 67-103.
13. Barboro P, Repaci E, D'Arrigo C, et al,. The role of nuclear matrix proteins binding to matrix attachment regions (MARs) in prostate cancer cell differentiation. PLoS One 2012; 7: e40617.
14. Barboro P, D'Arrigo C, Diaspro A, et al,. Unraveling the organization of the internal nuclear matrix: RNA-dependent anchoring of NuMA to a lamin scaffold. Exp Cell Res 2002; 279: 202-18.
15. Barboro P, D'Arrigo C, Repaci E, et al,. Proteomic analysis of the nuclear matrix in the early stages of rat liver carcinogenesis: identification of differentially expressed and MAR-binding proteins. Exp Cell Res 2009; 315: 226-39.
16. de Belle I, Cai S, Kohwi-Shigematsu T,. The genomic sequences bound to special at-rich sequence-binding protein 1 (satb1) in vivo in Jurkat T cells are tightly associated with the nuclear matrix at the bases of the chromatin loops. J Cell Biol 1998; 141: 335-48.
17. Guillou E, Ibarra A, Coulon V, et al,. Cohesin organizes chromatin loops at DNA replication factories. Genes Dev 2010; 24: 2812-22.
18. Barboro P, Alberti I, Sanna P, et al,. Changes in the cytoskeletal and nuclear matrix proteins in rat hepatocyte neoplastic nodules in their relation to the process of transformation. Exp Cell Res 1996; 225: 315-27.
19. Barboro P, Rubagotti A, Orecchia P, et al,. Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis. Cell Oncol 2008; 30: 13-26.
20. Carpenter B, McKay M, Dundas SR, et al,. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer 2006; 95: 921-7.
21. Alberti I, Parodi S, Barboro P, et al,. Differential nuclear matrix-intermediate filament expression in human prostate cancer in respect to benign prostatic hyperplasia. Cancer Lett 1996; 109: 193-8.
22. Alberti I, Barboro P, Barbesino M, et al,. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer. J Cell Biochem 2000; 79: 471-85.
23. Barboro P, Salvi S, Rubagotti A, et al,. Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression. Int J Oncol 2014; 44: 1589-998.
24. Mohler JM,. A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 2008; 22: 357-372.
25. Beck C, Robert I, Reina-San-Martin B, et al,. Poly(ADP-ribose) polymerases in double-strand break repair: focus on Parp1, Parp2 and Parp3. Exp Cell Res 2014; 329: 18-25.
26. Barreto-Andrade JC, Efimova EV, Mauceri HJ, et al,. Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther 2011; 10: 1185-93.
27. Schiewer MJ, Goodwin JF, Han S, et al,. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012; 2: 1134-49.
28. Ferraldeschi R, Welti J, Luo J, et al,. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2014; doi: 10.1038/onc.2014.115.
29. Razin SV,. The nuclear matrix and chromosomal DNA loops: is there any correlation between partitioning of the genome into loops and functional domains? Cell Mol Biol Lett 2001; 6: 59-69.
30. Aranda-Anzaldo A,. A structural basis for cellular senescence. Aging 2009; 1: 598-607.
31. Roth SY, Denu JM, Allis CD,. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
32. Leman ES, Getzenberg RH,. Nuclear structure as a source of cancer specific biomarkers. J Cell Biochem 2008; 104: 1988-93.
33. Lever E, Sheer D,. The role of nuclear organization in cancer. J Pathol 2010; 220: 114-25.
34. Misteli T,. Higher-order genome organization in human disease. Cold Spring Harb Perspect Biol 2010; 2: a000794.
35. Elcock LS, Bridger JM,. Exploring the effects of a dysfunctional nuclear matrix. Biochem Soc Trans 2008; 36: 1378-83.
36. Linnemann AK, Krawetz SA,. Maintenance of a functional higher order chromatin structure: the role of the nuclear matrix in normal and disease states. Gene Ther Mol Biol 2009; 13: 231-43.
37. Elcock LS, Bridger JM,. Exploring the relationship between interphase gene positioning, transcriptional regulation and the nuclear matrix. Biochem Soc Trans 2010; 38: 263-7.
38. Leman ES, Getzenberg RH,. Nuclear matrix proteins as biomarkers in prostate cancer. J Cell Biochem 2002; 86: 213-23.
39. Lakshmanan Y, Subong EN, Partin AW,. Differential nuclear matrix protein expression in prostate cancers: correlation with pathologic stage. J Urol 1998; 159: 1354-8.
40. Barboro P, Rubagotti A, Boccardo F, et al,. Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applications. Anticancer Res 2005; 25: 3999-4004.
41. Veltri RW, Isharwal S, Miller MC, et al,. Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: a prospective evaluation with up to 25 years of follow-up after radical prostatectomy. Prostate 2010; 70: 1333-9.
42. Ricci F, Rubagotti A, Zinoli L, et al,. Prognostic value of nuclear matrix protein expression in localized prostate cancer. J Cancer Res Clin Oncol 2012; 138: 1379-84.
43. Veltri RW, Christudass CS,. Nuclear morphometry, epigenetic changes, and clinical relevance in prostate cancer. Adv Exp Med Biol 2014; 773: 77-99.
44. Aranda-Anzaldo A, Dent MA, Martinez-Gómez A,. The higher-order structure in the cells nucleus as the structural basis of the post-mitotic state. Prog Biophys Mol Biol 2014; 114: 137-45.
45. Wang TY, Han ZM, Chai YR, et al,. A mini review of MAR-binding proteins. Mol Biol Rep 2010; 37: 3553-60.
46. Kraus WL, Hottiger MO,. PARP-1 and gene regulation: progress and puzzles. Mol Aspects Med 2013; 34: 1109-23.
47. Galande S, Kohwi-Shigematsu T,. Linking chromatin architecture to cellular phenotype: BUR-binding proteins in cancer. J Cell Biochem Suppl 2000; 35: 36-45.
48. Faraone-Mennella MR,. Chromatin architecture and functions: the role(s) of poly(ADP-RIBOSE) polymerase and poly(ADPribosyl)ation of nuclear proteins. Biochem Cell Biol 2005; 83: 396-404.
49. Tulin A, Chinenov Y, Spradling A,. Regulation of chromatin structure and gene activity by poly(ADP-ribose) polymerases. Curr Top Dev Biol 2003; 56: 55-83.
50. Yélamos J, Schreiber V, Dantzer F,. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med 2008; 14: 169-78.
51. Wu D, Zhang C, Shen Y, et al,. Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol Metab 2011; 22: 474-80.
52. Zhang J,. Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. Asian J Androl 2014; 16: 401-6.